Thermo Fisher Scientific TMO underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $592.0, with a high estimate of $670.00 and a low estimate of $550.00. Witnessing a positive shift, the current average has risen by 14.95% from the previous average price target of $515.00.
Investigating Analyst Ratings: An Elaborate Study
The standing of Thermo Fisher Scientific among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Raises | Equal-Weight | $555.00 | $475.00 |
| Rajesh Kumar | HSBC | Announces | Buy | $610.00 | - |
| Catherine Schulte | Baird | Announces | Outperform | $670.00 | - |
| Patrick Donnelly | Citigroup | Raises | Buy | $575.00 | $530.00 |
| David Toung | Argus Research | Raises | Buy | $550.00 | $540.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Thermo Fisher Scientific. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Thermo Fisher Scientific's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Thermo Fisher Scientific's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Thermo Fisher Scientific analyst ratings.
About Thermo Fisher Scientific
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%).
Thermo Fisher Scientific's Financial Performance
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Thermo Fisher Scientific's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -0.96%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Thermo Fisher Scientific's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Thermo Fisher Scientific's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.78, Thermo Fisher Scientific adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
